|1.||Raines, Ronald T: 12 articles (09/2014 - 03/2002)|
|2.||Matousek, Josef: 4 articles (08/2006 - 07/2002)|
|3.||Soucek, Josef: 4 articles (08/2006 - 07/2002)|
|4.||Soucek, J: 4 articles (01/2006 - 05/2002)|
|5.||Raines, R T: 4 articles (11/2001 - 04/2000)|
|6.||Gotte, Giovanni: 3 articles (05/2014 - 06/2003)|
|7.||Cui, Daxiang: 3 articles (01/2014 - 11/2010)|
|8.||Lee, J Eugene: 3 articles (01/2008 - 10/2003)|
|9.||Poucková, Pavla: 3 articles (08/2006 - 07/2002)|
|10.||Skvor, Jirí: 3 articles (08/2006 - 07/2002)|
01/01/2014 - "Site-specific RNase A activity was dramatically reduced in serum from multiple types of cancer patients."
03/01/2014 - "Similarly, RI evasive human pancreatic RNase variants mediated only small inhibiting effects on tumor cell growth at high concentrations, potentially reflecting inefficient cytosolic translocation. "
04/21/2010 - "Moreover, the acquired cytotoxicity does not seem to be specific for tumor cells: PEI-cationized native RNase A was also cytotoxic toward human monocytes."
06/01/2008 - "Rana pipiens oocytes contain two homologues of pancreatic ribonuclease A that are cytostatic and cytotoxic to human cancer cells. "
11/18/2005 - "This and two related variants of RNase A were more toxic to human cancer cells than was ONC. "
|2.||Melanoma (Melanoma, Malignant)
02/10/2004 - "On the other side, when RNase A conjugated to HYase or PEG was administered intraperitoneally into the mice bearing human melanoma, the antitumor effect was pronounced."
06/27/2003 - "The growth of human melanoma in nude mice is inhibited by RNase A oligomers in the order dimers < trimers < tetramers. "
09/01/1996 - "In addition, RNase A protection and in situ hybridization analyses documented expression of the gene, located on 3p14, in normal human melanocytes but not in malignant melanomas."
05/01/2002 - "The RNase A conjugates (classic and star) injected intravenously to mice bearing melanoma tumor caused a significant reduction in tumor volume following ten doses of 5 and 1 mg/kg, respectively. "
07/18/2002 - "Aspermatogenic activity was studied histologically following subcutaneous injections of RNase A and BS-RNase conjugates in ICR mice, and the antitumor activity in athymic nude mice with growing human melanoma with i.p. "
10/01/1983 - "No significant reduction of scrapie infectivity was observed with either RNase A or DNase I treatments. "
08/01/2009 - "RNase A treatment of partially purified PrP and of 263K scrapie brain homogenates was sufficient to increase the sensitivity of PrPSc to proteinase K degradation. "
01/01/1987 - "Preparations produced by repeated pelleting were treated with RNase A and/or 7 M-urea with no loss of scrapie infectivity. "
08/01/2009 - "Treatment with RNase A alone and PrP degradation by RNase A plus proteinase K in vitro, however, did not result in loss of scrapie infectivity compared with the effects of lithium aluminum hydride. "
02/20/2004 - "These RNase conjugates injected intravenously or intraperitoneally into the mice bearing melanoma, neuroblastoma or ovarian tumor caused significant reduction of transplanted tumors following ten daily doses of 2.5 and/or 1 mg/kg, respectively, while free RNase A or BS-RNase injected in doses of 10 mg/kg exerted only negligible antitumor activity. "
06/01/2008 - "Onconase, a member of the pancreatic ribonuclease A superfamily, is currently in Phase III clinical trials for treatment of unresectable malignant mesothelioma. "
12/01/2011 - "Onconase is a member of the ribonuclease A superfamily currently in phase IIIb clinical trials as a treatment for malign mesothelioma due to its cytotoxic activity selective against tumor-cells. "
12/06/2005 - "Moreover, BS-RNase monomers described herein are more toxic to human tumor cells than is any known variant or homologue of RNase A including Onconase, an amphibian homologue in phase III clinical trials for the treatment of unresectable malignant mesothelioma."
11/18/2005 - "Onconase (ONC), an amphibian member of the bovine pancreatic ribonuclease A (RNase A) superfamily, is in phase III clinical trials as a treatment for malignant mesothelioma. "
|1.||Pancreatic Ribonuclease (Ribonuclease A)
|2.||Deoxyribonuclease I (Nickase)
|5.||Small Interfering RNA (siRNA)
|1.||Quantum Dots (Quantum Dot)
|2.||Heterologous Transplantation (Xenotransplantation)